Literature DB >> 28551101

Key analogs of a uniquely potent synthetic vinblastine that contain modifications of the C20' ethyl substituent.

Oliver Allemann1, R Matthew Cross1, Manuela M Brütsch1, Aleksandar Radakovic1, Dale L Boger2.   

Abstract

A key series of vinblastine analogs 7-13, which contain modifications to the C20' ethyl group, was prepared with use of two distinct synthetic approaches that provide modifications of the C20' side chain containing linear and cyclized alkyl groups or added functionalized substituents. Their examination revealed the unique nature of the improved properties of the synthetic vinblastine 6, offers insights into the origins of its increased tubulin binding affinity and 10-fold improved cell growth inhibition potency, and served to probe a small hydrophobic pocket anchoring the binding of vinblastine with tubulin. Especially noteworthy were the trends observed with substitution of the terminal carbon of the ethyl group that, with the exception of 9 (R=F vs H, equipotent), led to remarkably substantial reductions in activity (>10-fold): R=F (equipotent with H)>N3, CN (10-fold)>Me (50-fold)>Et (100-fold)>OH (inactive). This is in sharp contrast to the maintained (7) or enhanced activity (6) observed with its incorporation into a cyclic C20'/C15'-fused six-membered ring.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antitumor drug; Tubulin; Vinblastine

Mesh:

Substances:

Year:  2017        PMID: 28551101      PMCID: PMC5538265          DOI: 10.1016/j.bmcl.2017.05.058

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

1.  Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloids.

Authors:  N Langlois; F Guéritte; Y Langlois; P Potier
Journal:  J Am Chem Soc       Date:  1976-10-27       Impact factor: 15.419

2.  10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.

Authors:  Hiroaki Gotoh; Katharine K Duncan; William M Robertson; Dale L Boger
Journal:  ACS Med Chem Lett       Date:  2011-12-08       Impact factor: 4.345

3.  Total synthesis of indole and dihydroindole alkaloids. IX. Studies on the synthesis of bisindole alkaloids in the vinblastine-vincristine series. The biogenetic approach.

Authors:  J P Kutney; T Hibino; E Jahngen; T Okutani; A H Ratcliffe; A M Treasurywala; S Wunderly
Journal:  Helv Chim Acta       Date:  1976-12-15       Impact factor: 2.164

4.  Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.

Authors:  Annie Tam; Hiroaki Gotoh; William M Robertson; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-09-19       Impact factor: 2.823

5.  Asymmetric total synthesis of vindorosine, vindoline, and key vinblastine analogues.

Authors:  Yoshikazu Sasaki; Daisuke Kato; Dale L Boger
Journal:  J Am Chem Soc       Date:  2010-09-29       Impact factor: 15.419

6.  Total synthesis and evaluation of vinblastine analogues containing systematic deep-seated modifications in the vindoline subunit ring system: core redesign.

Authors:  Kristin D Schleicher; Yoshikazu Sasaki; Annie Tam; Daisuke Kato; Katharine K Duncan; Dale L Boger
Journal:  J Med Chem       Date:  2013-01-04       Impact factor: 7.446

7.  Syntheses and biological evaluation of vinblastine congeners.

Authors:  Martin E Kuehne; William G Bornmann; Istvan Markó; Yong Qin; Karen L LeBoulluec; Deborah A Frasier; Feng Xu; Tshilundu Mulamba; Carol L Ensinger; Linda S Borman; Anne E Huot; Christopher Exon; Fred T Bizzarro; Julia B Cheung; Susan L Bane
Journal:  Org Biomol Chem       Date:  2003-06-21       Impact factor: 3.876

8.  Transannular Diels-Alder/1,3-dipolar cycloaddition cascade of 1,3,4-oxadiazoles: total synthesis of a unique set of vinblastine analogues.

Authors:  Erica L Campbell; Colin K Skepper; Kuppusamy Sankar; Katharine K Duncan; Dale L Boger
Journal:  Org Lett       Date:  2013-10-02       Impact factor: 6.005

9.  New insights into the mechanism and an expanded scope of the Fe(III)-mediated vinblastine coupling reaction.

Authors:  Hiroaki Gotoh; Justin E Sears; Albert Eschenmoser; Dale L Boger
Journal:  J Am Chem Soc       Date:  2012-08-07       Impact factor: 15.419

Review 10.  Total synthesis of vinblastine, related natural products, and key analogues and development of inspired methodology suitable for the systematic study of their structure-function properties.

Authors:  Justin E Sears; Dale L Boger
Journal:  Acc Chem Res       Date:  2015-01-14       Impact factor: 22.384

View more
  5 in total

1.  High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs.

Authors:  Aleksandar Radakovic; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2018-02-06       Impact factor: 2.823

2.  Ultra-potent vinblastine analogues improve on-target activity of the parent microtubulin-targeting compound.

Authors:  Aleksandar Radakovic; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2019-03-26       Impact factor: 2.823

Review 3.  Inverse Electron Demand Diels-Alder Reactions of Heterocyclic Azadienes, 1-Aza-1,3-Butadienes, Cyclopropenone Ketals, and Related Systems. A Retrospective.

Authors:  Jiajun Zhang; Vyom Shukla; Dale L Boger
Journal:  J Org Chem       Date:  2019-05-23       Impact factor: 4.354

4.  Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance.

Authors:  John C Lukesh; Daniel W Carney; Huijun Dong; R Matthew Cross; Vyom Shukla; Katharine K Duncan; Shouliang Yang; Daniel M Brody; Manuela M Brütsch; Aleksandar Radakovic; Dale L Boger
Journal:  J Med Chem       Date:  2017-08-31       Impact factor: 7.446

5.  The Difference a Single Atom Can Make: Synthesis and Design at the Chemistry-Biology Interface.

Authors:  Dale L Boger
Journal:  J Org Chem       Date:  2017-10-13       Impact factor: 4.354

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.